We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
Read MoreHide Full Article
QIAGEN N.V.’s (QGEN - Free Report) second-quarter 2021 adjusted earnings per share (EPS) were 67 cents (66 cents at constant exchange rate or CER), up 21.8% year over year (up 20% at constant exchange rate or CER). Moreover, the figure surpassed the Zacks Consensus Estimate by 1.5%.
Notably, the bottom line exceeded the company’s second-quarter guidance of 62-64 cents at CER.
The adjustment excludes the impact of certain non-recurring items like business integration, acquisition, restructuring-related expenses, and purchased intangibles amortization expenses, among others.
GAAP EPS for the quarter was 52 cents per share, improving significantly from the year-ago growth per share of 38 cents, reflecting an uptick of 36.8%.
Revenues in Detail
Net sales in the second quarter rose 27.9% on a year-over-year basis to $567.3 million (up 24% at CER). Also, the top line exceeded the Zacks Consensus Estimate by 0.9%. Top-line growth also exceeded the company’s second-quarter expectation of at least 20% year-over-year growth at CER.
Sales growth was recorded on improvements in non-COVID areas of the portfolio and trend improvement in the company’s core business.
Geographical Revenue Update
In the quarter under review, sales from the Americas (45% of sales) totaled $257 million, up 45% on a reported basis (up 44% at CER).
Revenues from Europe, Middle East and Africa (36% of sales) rose 23% reportedly (up 15% at CER) to $202 million.
Further, revenues from Asia-Pacific/ Japan (19% of sales) rose 10% year over year on a reported basis (up 4% at CER) to $109 million.
Segmental Details
As of the second quarter of 2021, QIAGEN had two major customer classes – Molecular Diagnostics and Life Sciences.
Molecular Diagnostics (representing 48% of net sales) revenues were up 33% on a reported basis (up 28% at CER) to $272 million.
Life Sciences (20% of total revenues) reported revenues of $296 million, up 24% on a reported basis (up 20% at CER).
Operational Update
Adjusted gross profit in the quarter under review rose 24.8% to $386.9 million. However, adjusted gross margin contracted 171 basis points (bps) to 68.2% due to a 35.3% rise in total cost of sales (adjusting for acquisition-related intangible amortization) to $180.4 million.
Sales and marketing expenses of QIAGEN rose 16.9% to $110.4 million year over year. Research and development expenses increased 63.9% year over year to $52.2 million whereas general and administrative expenses rose 29.9% year over year to $31 million.
Adjusted operating income (excluding items like acquisition-related intangible amortization, restructuring and integration, asset impairment) rose 20.9% year over year to $193.4 million in the second quarter. Adjusted operating margin however contracted 198 bps to 34.1%.
Financial Update
QIAGEN exited second-quarter 2021 with cash and cash equivalents, and short-term investments of $898 million, up from $791.7 million at the end of first-quarter 2021. Long-term debt was $1.94 billion in second-quarter 2021 compared with $1.93 billion in the prior quarter.
Cumulative net cash flow from operating activities at the end of second-quarter 2021 was $285 million compared with $150.9 million a year ago.
Guidance
In July ,QIAGEN updated its full-year view.
Full-year net sales are now expected to grow at least 12% at CER (a significant decline from earlier outlook of CER growth of 18-20%). Adjusted EPS for 2021 is now expected to be minimum $2.42 at CER (prior outlook of about $2.42-2.46 at CER).
Considering the Jun 30, 2021 exchange rate, currency movements against the U.S. dollar are still expected to create a positive impact of about 2-3 percentage points on net sales growth at actual rates for full-year 2021. Further, 2-3 cents of positive impact are expected on adjusted EPS.
For the third quarter, the company expects to report net sales of $483.8 million at CER (flat year over year). Adjusted EPS is expected to be about 52-53 cents at CER compared with 58 cents in the year-ago quarter.
Our Take
QIAGEN exited the second quarter of 2021 with better-than-expected revenues and earnings. It registered revenue growth across all geographies and both its operating segments in the second quarter.
However, a faster-than-expected vaccination uptake has led to a reduction in demand for COVID-19 testing. Taking this into consideration, earlier this month, the company had significantly reduced its 2021 guidance to reflect the COVID-19 testing trends for the second half of 2021. A weak margin scenario is an added concern.
Zacks Rank and Key Picks
QIAGEN currently carries a Zacks Rank #5 (Strong Sell).
Boston Scientific reported second-quarter 2021 adjusted EPS of 40 cents, which beat the Zacks Consensus Estimate by 8.1%. Second-quarter revenues of $3.08 billion outpaced the consensus mark by 4.4%.
West Pharmaceutical reported second-quarter 2021 adjusted EPS of $2.46, which surpassed the Zacks Consensus Estimate by 41.4%. Second-quarter revenues of $723.6 million outpaced the Zacks Consensus Estimate by 8.7%.
LabCorp reported second-quarter 2021 adjusted EPS of $6.13, surpassing the Zacks Consensus Estimate by 8.7%. Revenues of $3.84 billion exceeded the Zacks Consensus Estimate by 6.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
QIAGEN N.V.’s (QGEN - Free Report) second-quarter 2021 adjusted earnings per share (EPS) were 67 cents (66 cents at constant exchange rate or CER), up 21.8% year over year (up 20% at constant exchange rate or CER). Moreover, the figure surpassed the Zacks Consensus Estimate by 1.5%.
Notably, the bottom line exceeded the company’s second-quarter guidance of 62-64 cents at CER.
The adjustment excludes the impact of certain non-recurring items like business integration, acquisition, restructuring-related expenses, and purchased intangibles amortization expenses, among others.
GAAP EPS for the quarter was 52 cents per share, improving significantly from the year-ago growth per share of 38 cents, reflecting an uptick of 36.8%.
Revenues in Detail
Net sales in the second quarter rose 27.9% on a year-over-year basis to $567.3 million (up 24% at CER). Also, the top line exceeded the Zacks Consensus Estimate by 0.9%. Top-line growth also exceeded the company’s second-quarter expectation of at least 20% year-over-year growth at CER.
Sales growth was recorded on improvements in non-COVID areas of the portfolio and trend improvement in the company’s core business.
Geographical Revenue Update
In the quarter under review, sales from the Americas (45% of sales) totaled $257 million, up 45% on a reported basis (up 44% at CER).
QIAGEN N.V. Price, Consensus and EPS Surprise
QIAGEN N.V. price-consensus-eps-surprise-chart | QIAGEN N.V. Quote
Revenues from Europe, Middle East and Africa (36% of sales) rose 23% reportedly (up 15% at CER) to $202 million.
Further, revenues from Asia-Pacific/ Japan (19% of sales) rose 10% year over year on a reported basis (up 4% at CER) to $109 million.
Segmental Details
As of the second quarter of 2021, QIAGEN had two major customer classes – Molecular Diagnostics and Life Sciences.
Molecular Diagnostics (representing 48% of net sales) revenues were up 33% on a reported basis (up 28% at CER) to $272 million.
Life Sciences (20% of total revenues) reported revenues of $296 million, up 24% on a reported basis (up 20% at CER).
Operational Update
Adjusted gross profit in the quarter under review rose 24.8% to $386.9 million. However, adjusted gross margin contracted 171 basis points (bps) to 68.2% due to a 35.3% rise in total cost of sales (adjusting for acquisition-related intangible amortization) to $180.4 million.
Sales and marketing expenses of QIAGEN rose 16.9% to $110.4 million year over year. Research and development expenses increased 63.9% year over year to $52.2 million whereas general and administrative expenses rose 29.9% year over year to $31 million.
Adjusted operating income (excluding items like acquisition-related intangible amortization, restructuring and integration, asset impairment) rose 20.9% year over year to $193.4 million in the second quarter. Adjusted operating margin however contracted 198 bps to 34.1%.
Financial Update
QIAGEN exited second-quarter 2021 with cash and cash equivalents, and short-term investments of $898 million, up from $791.7 million at the end of first-quarter 2021. Long-term debt was $1.94 billion in second-quarter 2021 compared with $1.93 billion in the prior quarter.
Cumulative net cash flow from operating activities at the end of second-quarter 2021 was $285 million compared with $150.9 million a year ago.
Guidance
In July ,QIAGEN updated its full-year view.
Full-year net sales are now expected to grow at least 12% at CER (a significant decline from earlier outlook of CER growth of 18-20%). Adjusted EPS for 2021 is now expected to be minimum $2.42 at CER (prior outlook of about $2.42-2.46 at CER).
Considering the Jun 30, 2021 exchange rate, currency movements against the U.S. dollar are still expected to create a positive impact of about 2-3 percentage points on net sales growth at actual rates for full-year 2021. Further, 2-3 cents of positive impact are expected on adjusted EPS.
For the third quarter, the company expects to report net sales of $483.8 million at CER (flat year over year). Adjusted EPS is expected to be about 52-53 cents at CER compared with 58 cents in the year-ago quarter.
Our Take
QIAGEN exited the second quarter of 2021 with better-than-expected revenues and earnings. It registered revenue growth across all geographies and both its operating segments in the second quarter.
However, a faster-than-expected vaccination uptake has led to a reduction in demand for COVID-19 testing. Taking this into consideration, earlier this month, the company had significantly reduced its 2021 guidance to reflect the COVID-19 testing trends for the second half of 2021. A weak margin scenario is an added concern.
Zacks Rank and Key Picks
QIAGEN currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Boston Scientific Corporation (BSX - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific reported second-quarter 2021 adjusted EPS of 40 cents, which beat the Zacks Consensus Estimate by 8.1%. Second-quarter revenues of $3.08 billion outpaced the consensus mark by 4.4%.
West Pharmaceutical reported second-quarter 2021 adjusted EPS of $2.46, which surpassed the Zacks Consensus Estimate by 41.4%. Second-quarter revenues of $723.6 million outpaced the Zacks Consensus Estimate by 8.7%.
LabCorp reported second-quarter 2021 adjusted EPS of $6.13, surpassing the Zacks Consensus Estimate by 8.7%. Revenues of $3.84 billion exceeded the Zacks Consensus Estimate by 6.9%.